Related references
Note: Only part of the references are listed.Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction Rationale and Design of the PARAGON-HF Trial
Scott D. Solomon et al.
JACC-HEART FAILURE (2017)
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
Stefan D. t Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial
Barry Greenberg et al.
LANCET (2016)
Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial
William T. Abraham et al.
LANCET (2016)
Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model
Jennifer K. Rogers et al.
STATISTICS IN MEDICINE (2016)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer et al.
CIRCULATION (2015)
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved
Jennifer K. Rogers et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations The CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure)
Jennifer K. Rogers et al.
JACC-HEART FAILURE (2014)
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms Analysis of Repeat Hospitalizations
Jennifer K. Rogers et al.
CIRCULATION (2012)
Time to move on from otime-to-first': should all events be included in the analysis of clinical trials?
Stefan D. Anker et al.
EUROPEAN HEART JOURNAL (2012)
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
Jeffrey S. Borer et al.
EUROPEAN HEART JOURNAL (2012)
Wei, Lin and Weissfeld's marginal analysis of multivariate failure time data: should it be applied to a recurrent events outcome?
Chris Metcalfe et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2007)
Key issues in end point selection for heart failure trials: Composite end points
JD Neaton et al.
JOURNAL OF CARDIAC FAILURE (2005)
Nonparametric analysis of recurrent events and death
D Ghosh et al.
BIOMETRICS (2000)
Semiparametric regression for the mean and rate functions of recurrent events
DY Lin et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2000)